Axel Hoos

Axel Hoos

Presidente en
Cancer Research Institute
.
56 años
Health Technology
Commercial Services
Health Services

Perfil

Axel Hoos was the founder of Imugene Ltd. (founded in 2013) and held the title of Independent Non-Executive Director.
He is currently the Co-Chairman at Cancer Research Institute, Director at Nextpoint Therapeutics, Inc. (since 2023), and Trustee at Albert B. Sabin Vaccine Institute, Inc. Dr. Hoos has previously served as the Chief Executive Officer & Director at Scorpion Therapeutics, Inc. (2021-2024), Senior Director-Clinical Development at Agenus, Inc. (2001-2005), Independent Director at TCR2 Therapeutics, Inc. (2020-2023), and Global Medical Lead-Immunology & Oncology at Bristol Myers Squibb Co. (2005-2011).
He has also held the position of Senior VP & Therapeutic Area Head-Oncology at GlaxoSmithKline Pharmaceuticals Ltd. Dr. Hoos obtained his doctorate degree from Ruprecht-Karls-Universität Heidelberg in 1997.

Cargos activos de Axel Hoos

EmpresasCargoInicio
Director/Miembro de la Junta -
Presidente -
Director/Miembro de la Junta 21/03/2023

Antiguos cargos conocidos de Axel Hoos.

EmpresasCargoFin
Director Ejecutivo 04/01/2024
TCR2 THERAPEUTICS INC. Director/Miembro de la Junta 01/06/2023
IMUGENE LIMITED Fundador 19/11/2021
BRISTOL-MYERS SQUIBB COMPANY Corporate Officer/Principal 01/01/2011
AGENUS INC. Corporate Officer/Principal 01/01/2005
Ver el detalle de la experiencia de Axel Hoos.

Formación de Axel Hoos.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

80

Relaciones de 1er grado

10

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas10

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Services

Consumer Services

Health Technology

Health Technology

Commercial Services